Therapeutic Responses to Efgartigimod for Generalized Myasthenia Gravis in Japan-Reference-Cited by-同舟云学术

Therapeutic Responses to Efgartigimod for Generalized Myasthenia Gravis in Japan

Published:2024-06 Issue:3 Volume:14 Page:
ISSN:2163-0402
Container-title:Neurology Clinical Practice
language:en
Short-container-title:Neur Clin Pract

Author:

Suzuki Shigeaki¹^ORCID,Uzawa Akiyuki¹^ORCID,Nagane Yuriko¹^ORCID,Masuda Masayuki¹^ORCID,Konno Shingo¹^ORCID,Kubota Tomoya¹^ORCID,Samukawa Makoto¹^ORCID,Ishizuchi Kei¹^ORCID,Tokuyasu Daiki¹^ORCID,Handa Hideo¹^ORCID,Yasuda Manato¹^ORCID,Kawaguchi Naoki¹^ORCID,Kimura Takashi¹^ORCID,Suzuki Yasushi¹^ORCID,Sugimoto Takamichi¹^ORCID,Minami Naoya¹^ORCID,Takahashi Masanori P.¹^ORCID,Murai Hiroyuki¹^ORCID,Utsugisawa Kimiaki¹^ORCID

Affiliation:

1. Department of Neurology (SS, KI, DT), Keio University School of Medicine, Tokyo; Department of Neurology (AU, HH, MY), Graduate School of Medicine, Chiba University; Department of Neurology (YN, KU), Hanamaki General Hospital; Department of Neurology (MM), Tokyo Medical University; Department of Neurology (SK), Toho University Ohashi Medical Center, Tokyo; Division of Health Sciences (T. Kubota, MPT), Department of Clinical Laboratory and Biomedical Sciences, Osaka University Graduate School of...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Link

https://www.neurology.org/doi/pdfdirect/10.1212/CPJ.0000000000200276

Reference19 articles.

1. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders

2. International Consensus Guidance for Management of Myasthenia Gravis

3. Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management

4. Understanding the burden of refractory myasthenia gravis

5. Performance of different criteria for refractory myasthenia gravis

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients;Journal of Neurology;2024-07-30

2. Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients;Frontiers in Neurology;2024-06-17

3. Targeting autoimmune mechanisms by precision medicine in Myasthenia Gravis;Frontiers in Immunology;2024-06-06

4. Real-World Case Series of Efgartigimod for Japanese Generalized Myasthenia Gravis: Well-Tailored Treatment Cycle Intervals Contribute to Sustained Symptom Control;Biomedicines;2024-05-30